Promising results have emerged from the first-ever clinical drug trial for the condition, including improvements in weight gain, bone structure and heart health.
A third of children placed on the drug Ionafarnib demonstrated a greater than 50 per cent increase in annual rate of weight gain or switched from weight loss to weight gain, due to increased muscle and bone mass.
On average skeletal rigidity, which was highly abnormal in patients at the time of the trial, improved to normal levels after treatment, the 'Daily Mail' reported.
Arterial stiffness, which is linked with an increased risk of having a heart-attack, decreased by 35 per cent.
The genetic condition, which affects one in eight million people, causes the body to age eight times faster than normal.
The disorder is said to have inspired the F Scott Fitzgerald novella and Brad Pitt movie The Curious Case of Benjamin Button, in which the character is born an old man and ages backwards.
"To discover that some aspects of damage to the blood vessels in Progeria cannot only be slowed by the drug called lonafarnib, but even partially reversed within just 2.5 years of treatment is a tremendous breakthrough, because cardiovascular disease is the ultimate cause of death in children with Progeria," study author Dr Leslie Gordon, from Boston Children's Hospital, said.
The two-and-a-half year drug trial involved 26 children with the disease - which was three-quarters of the known Progeria cases when it started.
The study was published in the journal Proceedings of the National Academy of Sciences.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app